Go DBI dimethylbiguanide
Go

Dbi dimethylbiguanide

Dbi Dimethylbiguanide (DBI. Dimethylbiguanid) is a drug of glucose-lowering action. When combined with the use of insulin can significantly reduce the dose of the latter. Lowers blood sugar levels in all forms of diabetes. Its action is inversely proportional to the amount of insulin consumed.

Pharmachologic effect. DBI promotes the anaerobic burning of glucose to lactic acid. Maximum action after 6 hours.

Indications. Diabetes mellitus (all forms).

Dosage. Treatment begins with small doses of 0.05 twice a day, gradually increasing it to 0.10–0.15 three times a day, at the same time reducing the dose of insulin injected until it is completely canceled.

Side effects. In the first week of use of DBI, anorexia, nausea, vomiting, diarrhea, and dizziness may occur. By reducing the dose of the drug, these phenomena can pass.

Late side effects occur after 4-16 weeks from the beginning of the reception of DBI: drowsiness, weakness, weight loss; with a decrease in dose or withdrawal of the drug, these phenomena disappear. Serious complications with damage to internal organs are not observed.

Go

Mode of application. Inside with a meal, which reduces side effects.

Form release. Tablets of 0.05-0.1.

D-860 - N (4-methyl-benzene-sulfonyl) –T1-butyl-urea. Antibacterial properties in the BZ-55 molecule are associated with the NH group, which is linked to the benzene ring. As a result of the replacement of this amide group of the methyl (CH3) drug, the side effects associated with the antibacterial effect of sulfonamides were lost. At the same time, sugar-lowering properties are preserved. They are associated with the presence of a sulfanamide series of the SO 2 group in these preparations.

Pharmachologic effect. Reduces blood sugar and reduces its excretion in the urine with diabetes.

Indications. Diabetes in individuals who used no more than 40- 60 IU of insulin per day.

Contraindications. A mild form of diabetes, compensated by the use of diet. Diabetes in adolescence and childhood. Tendency to acidosis, pre-comatose and comatose state. Pregnancy. Liver and kidney disease. Infectious diseases. Leukopenia Thrombocytopenia.

Side effects Dry mouth. Headache. Itching, Other allergic phenomena (urticaria, etc.). Canceling the drug leads to their disappearance.

Mode of application. On the first day, appoint 1,5-3,0; on the second day — 1.0–2.5; in the third - 0.5-2.0; in the fourth and subsequent days - 0.5-1.5.

The drug is taken half an hour after a meal. Daily dose of more than 1.0 is given in two doses. When transferring a patient from insulin to D-860 treatment, insulin can be canceled immediately if the dose does not exceed 30-U per day. Constant monitoring of blood sugar and urine is necessary.

Form release. Tablets 0.5 (butamid 0.25).

Refers to list B.